# Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients

> **NCT06535529** · PHASE3 · RECRUITING · sponsor: **Helwan University** · enrollment: 60 (estimated)

## Conditions studied

- Acute Decompensated Heart Failure

## Interventions

- **DRUG:** Acetazolamide
- **DRUG:** Dapagliflozin 10mg

## Key facts

- **NCT ID:** NCT06535529
- **Lead sponsor:** Helwan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-24
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06535529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06535529, "Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06535529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*